Univerzita Palackeho V Olomouci

Ustav Experimentalni Botaniky Av Cr, V.v.i.

Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky

Freie Universitat Berlin

Univerzita Palackeho

Bioapex, S.r.o.

Institute of Experimental Botany, Academy of Sciences of the Czeck Republic

Biopatterns, S.r.o.

Institute of Experimental Botany, Academy of Sciences of the Czech Republic

Fakultni Nemocnice Olomouc

Univerzita Palackego V Olomouci

Syngenta Participations Ag

Marek Zatloukal

Miroslav Strnad

Karel Dolezal

Lukas Spichal

Jiri Voller

Lucie Plihalova

Igor Popa

René Lenobel

Jiri Gruz

Frank J Massino

Stefaan Werbrouck

Vladimir Krystof

Libor Havlicek

Borivoj Vojtesek

Lucie Szucova

Ondrej Plihal

Radoslav Koprna

Jan Holub

Hana Vylicilova

Jaroslav Nisler

Thomas Schmülling

Tomas Werner

Radek Jorda

Petr Galuszka

Jitka Vostalova

Alena Rajnochova Svobodova

Jitka Ulrichova

Eva Reznickova

Alena Kadlecova

Vaclav Mik

Jana Klaskova

Johannes Van Staden

Marketa Gemrotova

Dana Hradecká

Aloka Kumari

Petr Mlejnek

Jitka Frebortova

Ponnusamy Baskaran

Stjepan Uldrijan

Adeyemi Oladapo Aremu

Jan Hanus

Jana Bibova

Magdalena Bryksova

Lenka Zahajska

Jan Walla

Gabriel Gonzales

Noemi Bucharova

Petr Kanovsky

Wolfgang Mikulits

Tomas Gucky

Tomas Pospisil

Dardan Klos

Jarmila Balonova

Ludek Frohlich

Thomas Schmulling

Frantisek Skarupa

Lucie RÁROVÁ

Dana Hradeck

A para-topolin mesylate salt and its crystalline form is disclosed. Cosmetic and therapeutic applications, and compositions containing this compound, are also disclosed. Mesylate salt of para-topolin has a wide range of biological activities, including antioxidative, anti-inflammatory, anti-senescent and anti-aging while showing low toxicity and excellent solubility.

Mesylate salt of para-topolin, compositions containing said salt and use thereof

Heterocyclic nitrogen-containing purine derivatives and their use in the medicinal applications and compositions containing these derivatives is disclosed. A new generation of compounds possessing selective antineurodegenerative properties on neuronal cells and tissues and that can be particularly used in the treatment and prophylaxis of neurodegenerative disease, particularly in the treatment and prophylaxis of Parkinson's disease is also disclosed.

Heterocyclic nitrogen-containing purine derivatives, pharmaceutical preparations containing these derivatives and their use in neuroprotection

The invention relates to N,N-disubstituted-9-(2-oxacycloalkyl)-9H-purine-2, 6-diamine derivatives and their use as drugs and cosmetics. The compounds of the present invention exhibit a number of biological activities associated with oxidative stress inhibition, especially anti-aging, anti-inflammatory and anti-neurodegenerative biological activities. The invention also relates to cosmetic and pharmaceutical compositions containing such derivatives as active agents.

9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders

The invention relates to substituted 6-anilino-9-heterocyclylpurine derivatives of formula I wherein R denotes one to five substituents independently selected from the group hydrogen, halogen, hydroxy, amino, alkyloxy and alkyl group, R2 is selected from the group comprising amino, halogen, hydroxy, thio, and alkylthio group, Cyc is five- or six-membered heterocyclic ring containing one oxygen atom. The derivatives are useful for inhibition of plant stress.

Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress

6-aryl-9-glycosidpurines of general formula I and pharmaceutically acceptable salts thereof with alkali metals, ammonia, amines, or addition salts with acids, wherein

6-aryl-9-glycosylpurines and use thereof

6-aryl-9-glycosidpurines of general formula I and pharmaceutically acceptable salts thereof with alkali metals, ammonia, amines, or addition salts with acids, whereinGly represents &#x3b2;-D-arabinofuranosyl or &#x3b2;-D-2'-deoxyribofuranosyl,Ar represents benzyl or furfuryl, each of which can be unsubstituted or substituted by one or more, preferably one to three, substituents selected from the group comprising hydroxyl, alkyl, halogen, alkoxy, amino, mercapto, carboxyl, cyano, amido, sulfo, sulfamido, acyl, acylamino, acyloxy, alkylamino, dialkylamino, alkylmercapto, trifluoromethyl, trifluoromethoxy, for use as antisenescent and UV protective compounds in animals.

6,8-Disubstituted-9-(heterocyclyl)purines for use in pharmaceutical and cosmetic compositions and applications are provided. These 6,8-disubstituted-9-(heterocyclyl)purines have a wide range of biological activities, including for example antioxidant, anti-inflammatory, anti-senescent, anti-aging, as well as well as other activities which are especially useful in pharmaceutical and cosmetic applications. Compositions may include additional excipients and auxiliary substances. Methods of treatment of animals, mammals, plants, cells, yeast, and cells in tissue culture are also disclosed.

6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications

Substituted 1,2,3-thiadiazol-5yl-urea derivatives, their use as anti-senescence and anti-stress factors of plant cells, organs and the whole plant, and preparations containing these derivatives.

1,2,3-thiadiazol-5yl-urea derivatives, use thereof for regulating plant senescence and preparations containing these derivatives

The invention relates to substitution derivatives of N-benzyladenosine-5'-monophosphate of the general formula I, wherein (R)represents 1 to 4 substituents (n is in the range 1-4), which can be the same or different, and R is selected from the group comprising Cto Calkyl, Cto Calkoxy, amino, halogen, hydroxy, mercapto and nitro groups, and the pharmaceutically acceptable salts thereof. This invention also relates to methods of their preparation, their use as medicaments and in other biotechnological applications, and a therapeutic composition containing these derivatives.

[object Object]

The invention relates to new substituted 6-(2-aminobenzylamino)purines, represented by the general formula I, which can be used in CDK inhibition, in particular, in the treatment of viral infections and diseases involving cell proliferation. The invention further includes pharmaceutical preparations containing substituted 6-(2-aminobenzylamino)purines.

Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds

Certain 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts of the general formula are provided wherein Rand Rare as defined in the specification. These 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts are useful in compositions for treating mammalian cells, and especially human skin cells, in order to ameliorate the adverse effects of aging, treat skin disease states, treat immunological responses resulting from or associated with inflammation, and the like.

6, 9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions

Novel heterocyclic derivatives based on N-substituted adenine, having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells and methods of their preparation. Included are also pharmaceutical compositions, cosmetic preparations and growth regulators, which contain these derivatives as active compound and the use of these derivatives for the preparation of drugs, cosmetic preparations, in biotechnological processes, in cosmetics and in agriculture.

The invention relates to substituted 6-(2-hydroxybenzylamino)purines of general formula I, to their activity as cyclin-dependent kinases 2, 5, 7 and 9 inhibitors and to their use as medicaments, particularly in the treatment of disorders involving cell proliferation or inflammation. The invention further includes pharmaceutical compositions containing the substituted 6-(2-hydroxybenzylamino)purines. 

Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives

The invention relates to substituted 6-anilinopurine derivatives of the general formula I, wherein R denotes one to five substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, alkyloxy and alkyl group, and R2 denotes amino, halogen, nitro, thio, alkylthio or alkyl group for use as inhibitors of cytokinin oxidase/dehydrogenase. The invention also relates to the compositions containing these derivatives.

Substituted 6-anilinopurine derivatives as inhibitors of cytokinin oxidase/dehydrogenase and preparations containing these derivatives

The invention concerns novel substitution derivatives of N-benzyladenosine having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells. This invention also relates to the methods of preparation of these N-benzyladenosine derivatives and their use as drugs, cosmetic preparations and growth regulators comprising these derivatives as active compound and use of these derivatives for preparation of pharmaceutical compositions, in biotechnological processes, in cosmetics and in agriculture.

Growing community of inventors

Sumperk, Czechia

Marek Zatloukal